Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq -- Ignore unavailable to you. Want to Upgrade?

To: Clarksterh who wrote (306)	10/21/2007 12:02:16 PM
From: mlrb2113	Respond to of 332

<<Dr. Fleming is President and Chief Executive Officer of Kinexum LLC, a prominent life sciences consulting firm. The use of the present tense is odd. Is he not leaving his old job?>> I didn't notice that, but it strengthens my first impression that AGIX hired him as a consultant (in desperation?) to try to save 1067 from the liver tox issue and possibly other potential problems. I don't think Rob would've left voluntarily or been forced out after all his years there if things looked rosy.

To: Clarksterh who wrote (306)	10/25/2007 11:28:43 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 332

Draft Guidance for Industry on Drug Induced Liver Injury: fda.gov Excerpt: In general, the type of liver injury that leads to severe DILI is a predominantly hepatocellular injury. Hepatocellular injury is indicated by rises in serum AT activities reflecting release of alanine or aspartate aminotransferase (ALT or AST) from injured liver cells. The ability to cause some hepatocellular injury, however, is not a reliable predictor of a drug’s potential for severe DILI. Many drugs that cause transient rises in serum AT activity do not cause progressive or severe DILI, even if drug administration is continued. It is only those drugs that cause hepatocellular injury extensive enough to affect the liver’s functional ability to clear bilirubin from the plasma or to synthesize prothrombin and other coagulation factors that cause severe DILI. It is important to identify those drugs as rapidly as possible.